Level B· Emerging clinical evidence with positive signalsClinical TrialPubMed

[The hopes of the mesenchymal stem cells in regenerative medicine].

Bourin P., Gadelorge M.

Clinical Trial on Cardiovascular Disease, Immune Modulation, published in Transfus Clin Biol (2007) — summary generated from the PubMed abstract.

Open my reading list
Level B· Emerging clinical evidence with positive signalsEvidence level of this study

Several human studies show positive signals, while research methods and sample sizes continue to develop.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Clinical Trial
Journal
Transfus Clin Biol (2007)
Country
France
Reported sample size
—
Source database
PubMed
PMID
17513155
DOI
10.1016/j.tracli.2007.03.012

Abstract (original English)

The mesenchymal stem cells are a cell population of bone marrow, which have the capacity to differentiate towards all the cells from the locomotor apparatus. They also have immunomodulatory properties and can contribute to tissue repair, thanks to the secretion of many growth factors. Such cells are also found in the cord blood. In the same way, very close stem cells exist in great quantity in fat tissue. These cells are very good candidates in regenerative medicine. Besides, several clinical trials were carried out in order to highlight their effectiveness mainly in osseous repair and also during hematopoietic stem cells graft or cardiac repair after infarction. However, these trials will be able to develop fully only with the condition that culture techniques meeting the conditions of good manufacturing practice are set-up. This presentation gives a progress report on the whole of these subjects.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Several human studies show positive signals, while research methods and sample sizes continue to develop.

How we grade evidence
Adipose TissueBone Marrow CellsCell Culture TechniquesCell DifferentiationFibroblastsHematopoietic Stem Cell TransplantationHematopoietic Stem CellsHumansMesenchymal Stem Cell TransplantationMesenchymal Stem Cells

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research